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A nanotherapeutic agent composed of a magnetic iron oxide 
core and a temperature-responsive polymer shell for use as 
both nanoheater and a drug carrier has been developed. These 
magnetic nanocomposites (MNCs) allow for a triggered release 
of drugs as a consequence of hyperthermia and tumour acidic 
pH, through the breaking of pH and heat labile Schiff  base bonds 
that bind the drug molecules to the polymer. The properties of 
the MNCs were studied, as well as the kinetics of drug release 
under diff erent pH and temperature conditions.
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Doxorubicin loaded dual pH- and thermo-
responsive magnetic nanocarrier for combined
magnetic hyperthermia and targeted controlled
drug delivery applications†
Aziliz Hervault,a,b,c Alexander E. Dunn,d May Lim,d Cyrille Boyer,e Derrick Mott,c
Shinya Maenosono*c and Nguyen T. K. Thanh*a,b
Magnetic nanocarriers have attracted increasing attention for multimodal cancer therapy due to the
possibility to deliver heat and drugs locally. The present study reports the development of magnetic nano-
composites (MNCs) made of an iron oxide core and a pH- and thermo-responsive polymer shell, that can
be used as both hyperthermic agent and drug carrier. The conjugation of anticancer drug doxorubicin
(DOX) to the pH- and thermo-responsive MNCs via acid-cleavable imine linker provides advanced fea-
tures for the targeted delivery of DOX molecules via the combination of magnetic targeting, and dual pH-
and thermo-responsive behaviour which oﬀers spatial and temporal control over the release of DOX. The
iron oxide cores exhibit a superparamagnetic behaviour with a saturation magnetization around 70 emu
g−1. The MNCs contained 8.1 wt% of polymer and exhibit good heating properties in an alternating mag-
netic ﬁeld. The drug release experiments conﬁrmed that only a small amount of DOX was released at
room temperature and physiological pH, while the highest drug release of 85.2% was obtained after 48 h
at acidic tumour pH under hyperthermia conditions (50 °C). The drug release kinetic followed Kors-
meyer–Peppas model and displayed Fickian diﬀusion mechanism. From the results obtained it can be
concluded that this smart magnetic nanocarrier is promising for applications in multi-modal cancer
therapy, to target and eﬃciently deliver heat and drug speciﬁcally to the tumour.
Introduction
Magnetic nanoparticles (NPs) have emerged as a promising
technology for their potential use in biomedical applications,
and more particularly for cancer treatment and diagnosis,
such as magnetic resonance imaging (MRI),1–3 cell separ-
ation,4,5 magnetic hyperthermia6–8 or drug delivery.9–11 In par-
ticular, iron oxide NPs (IONPs), already approved by the US
Food and Drug Administration (FDA), have been greatly inves-
tigated due to their good biocompatibility, low toxicity and
ease of synthesis. Below a certain size (around 27 nm),12
IONPs become superparamagnetic. Superparamagnetic NPs
are more suitable than ferri- or ferromagnetic NPs for
hyperthermia applications as they do not retain any magneti-
zation once the magnetic field is removed. Hyperthermia is
known as a treatment where tumours are exposed to increased
temperatures (40–45 °C)13 causing cancer cells to undergo
apoptosis,14 while sparing normal cells, as cancer cells have
greater sensitivity to heat than healthy cells.15,16 When super-
paramagnetic NPs are subjected to an alternating magnetic
field (AMF), these NPs generate heat through Néel and Brow-
nian relaxation losses. Magnetic hyperthermia has already
shown its therapeutic eﬃcacy in clinical trials.17,18
Hyperthermia is also often used as an adjuvant therapy
with radio- or chemotherapy,19 as heat makes cancer cells
more sensitive to the eﬀect of radiation15 and antineoplastic
agents.16,20 An enhanced therapeutic eﬃcacy of chemotherapy
in combination with hyperthermia has been demonstrated in
many clinical trials,21–24 resulting in a synergistic eﬀect of the
cancer therapy. Increased anti-cancer drug accumulation in
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tumour and thermal enhancement of drug cytotoxicity mainly
caused by an improved intracellular uptake of drugs due to an
increased cell membrane permeability, inhibition of DNA-
repair of the chemically induced lethal or sublethal damages,
and acceleration of the cytotoxic chemical reaction, are among
the most important mechanisms behind the synergistic eﬀect
of thermo-chemotherapy.25,26 One of the major advantage of
using magnetic NPs as drug carrier over conventional chemo-
therapy is that NPs can be potentially injected and further con-
centrated anywhere in the body through magnetic targeting,
allowing the treatment of all kinds of tumours by delivering
drugs to specific locations in the body, therefore reducing the
side eﬀects.
While relatively recent, the approach of combining mag-
netic hyperthermia and drug delivery features in the same for-
mulation to eﬀectively deliver heat and drug locally and
benefit from the synergistic eﬀect has already shown promis-
ing results.27 Several studies reported the enhanced cytotoxi-
city to cancer cells of drugs when combined with magnetic
hyperthermia in vitro or in vivo.28–32 Moreover, combining drug
delivery with magnetic hyperthermia has also proven itself to
be a useful technique in overcoming multidrug resistance on
drug-resistant cancer.33,34
Smart polymers, a class of materials that respond to
environmental stimuli such as pH or temperature, represent a
very attractive choice of polymer coating for biomedical appli-
cations and particularly drug delivery to achieve a controlled
release of the drug.35 Thermo-responsive polymers can either
exhibit a upper critical solution temperature (UCST) or a lower
critical solution temperature (LCST). Polymers displaying a
UCST become soluble upon heating while the LCST is the
temperature at which polymers undergo a reversible confor-
mational change from a swollen hydrophilic state to a shrun-
ken hydrophobic one resulting in a volume decrease due to
expelling of the aqueous content from its chains.36,37 As a con-
sequence, the use of thermo-responsive polymers having a
LCST in the hyperthermia temperature range to magnetically
remotely trigger the release of the drug is desirable. At physio-
logical temperature, the drug is retained in the composite.
When heat is produced by the magnetic NPs in an AMF, the
surrounding temperature rises above the LCST and triggers the
release of the drug in a temporal control manner. pH-respon-
sive nanocarriers exploit the physiological diﬀerences found
between healthy and tumour tissues, as extracellular tumour
environment often exhibits acidic pH (from 5.7 to mostly
lower than 7.2) as compared to normal tissue (ca. 7.4).38,39
Moreover, if nanocarriers are taken up by cells through endo-
cytosis, they will be trapped in intracellular organelles such as
endosomes and lysosomes, which have even lower pH (6.0–6.5
in early endosomes, 5.0–6.0 in late endosomes and 4.5–5.0 in
lysosomes).
Our work reports the development and characterization of
a dual pH- and thermo-responsive MNC drug carrier suitable
for multi-modal cancer therapy, by combining magnetic tar-
geting, hyperthermia and controlled drug delivery. The dual
stimuli-responsive features oﬀer spatial and temporal control
over the release of the anticancer drug, which is triggered as a
consequence of hyperthermia and tumour acidic pH. The
MNCs are composed of an iron oxide core, synthesized by a
microwave-assisted co-precipitation method,40 and a thermo-
responsive polymer shell. This polymer was previously
designed and used by A. E. Dunn et al.,41 in the development
of nanocomposites with an acicular magnetite core for con-
trolled drug delivery and MRI applications. However, the mag-
netic hyperthermia of those nanoparticles were not reported
and a dye was used as a model for the anticancer drug. While,
in this work, a high heating eﬃciency iron oxide spherical
magnetic nanoparticles synthesized in our lab using a micro-
wave40 was conjugated with the polymer. The thermo-respon-
sive copolymer was engineered to have its LCST in the
hyperthermia temperature range. The heating performances of
the MNCs were assessed and the MNCs were subsequently
loaded with the anticancer drug doxorubicin (DOX) through
formation of pH-sensitive imine bonds between the amine
group of DOX and the aldehyde group of the copolymer
(Fig. 1). The loading and in vitro release profiles under
diﬀerent temperatures and pH conditions were studied using
UV-Vis spectroscopy.
Fig. 1 Synthesis of the DOX-MNCs.
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Experimental
Materials
Iron(II) chloride tetrahydrate (FeCl2·4H2O, purity 99%), iron(III)
chloride hexahydrate (FeCl3·6H2O, purity >99%), sodium car-
bonate (Na2CO3, purity 99%), hydrochloric acid (HCl, 37 vol%),
poly(ethylene glycol) methyl ether methacrylate (PEGMA,
Mn = 300 g mol
−1), di(ethylene glycol) methyl ether methacry-
late (DEGMA, purity 95%), 3-(trimethoxysilyl)propyl methacry-
late (TMSPMA, purity 98%), 3-vinylbenzaldehyde (VBA, purity
97%), 4,4′-azobis(4-cyanovaleric acid) (ACVA, purity ≥75%),
4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (CPPA,
purity 97%), chloroform-d NMR solvent, triethylamine (TEA,
purity 98%), acetonitrile (purity 99.8%), toluene (purity
99.8%) and petroleum ether were purchased from Sigma
Aldrich. Tetrahydrofuran (THF, stabilizer free, purity 99.8%)
was provided from Wako Chemicals. Ethanol (purity 99.5%)
was obtained from Nacalai Tesque Japan. All the reagents were
used as purchased without any further purification.
Synthesis of P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA])
The P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer was
synthesized by reversible addition fragmentation chain trans-
fer (RAFT) polymerization according to a previous publication
with some modifications.41 The PEGMA and DEGMA mono-
mers were mixed in a molar ratio 1 : 2.2 with the CPPA as the
RAFT chain transfer agent and ACVA as the initiator. Under Ar
atmosphere, anhydrous acetonitrile was added to the flask and
the mixture was bubbled with Ar for 30 min. After degassing,
the mixture was heated to 70 °C and maintained at this tem-
perature for 5 h. The resulting polymer was then washed using
petroleum ether and dried under vacuum overnight. A chain
extension was then carried out by mixing the dry P(DEGMA-co-
PEGMA) polymer used as macro-RAFT agent with ACVA
initiator, TMSPMA and VBA in toluene. The monomers were
added in a ratio of 1 : 4. This mixture was then degassed under
Ar and heated to 90 °C for 4 h. The resulting polymer was
again purified by precipitation in petroleum ether, and dried
under vacuum.
Synthesis of IONPs
IONPs were synthesized following a modified procedure con-
sisting of microwave-assisted co-precipitation of Fe(II) and
Fe(III) with Na2CO3 and the aid of a SP-Discovery Microwave
(CEM, USA).40 FeCl2·4H2O (0.4 mmol) and FeCl3·6H2O
(0.8 mmol) were dissolved in 20 mL of Milli-Q water (Millipore,
18.2 MΩ cm−1), transferred into a vial and sealed with a
pressure cap. The solution was heated to 60 °C (300 W), and
Na2CO3 aqueous solution (4 mL, 1 M) was added drop wise at
a rate of 2 mL min−1 using a syringe pump (KD Scientific Inc.,
KDS100). The solution was kept at this temperature for 20 min
before allowing to cool down to room temperature. The NPs
were then washed three times with ultrapure water by mag-
netic separation.
Grafting of the copolymer onto the IONP surface
The grafting of the polymer P(DEGMA-co-PEGMA-b-[TMSPMA-
co-VBA]) onto the IONP surface was realized through a silanisa-
tion reaction between the trimethoxysilane groups of the
polymer and the hydroxyl groups present on the surface of the
bare IONPs, forming a covalent Si–O–Fe bond. Freshly syn-
thesized naked IONPs (20 mg) were mixed with 60 mg of
P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer dissolved
in 20 mL of ethanol. The mixture was acidified to pH = 2–3 by
adding 50 μL of HCl, sonicated for 10 min and then stirred at
room temperature for 24 h. The copolymer-functionalized
IONPs, hereafter referred to as composite NPs (MNCs) were
then washed by magnetic separation two times with ethanol
and once with ultrapure water before being redispersed in
ultrapure water for further use.
Characterization of the MNCs and their components
1H nuclear magnetic resonance (NMR) spectroscopy was used
to monitor the polymerization reaction advancement and
analyze the polymer composition. 1H NMR spectra were
recorded on a Bruker Avance III 400 MHz NMR spectrometer
using chloroform-d as a solvent. Number average molecular
weight (Mn) and polydispersity (PDI = Mw/Mn) of the syn-
thesized polymers were measured by size exclusion chromato-
graphy (SEC) performed on a Shimadzu Prominence high-
performance liquid chromatograph equipped with a LC-20AD
liquid chromatograph, a RID-10A refractive index detector, a
CTO-20A column oven and a DGU-20A3 degasser. THF (stabili-
zer free) was used as the mobile phase. Samples were pre-
pared by dissolving 5 mg of vacuum-dried polymer in 2 mL of
THF. The molecular weights of the polymers were determined
by a conventional calibration using polystyrene standards
ranging from 5.8 × 102 g mol−1 to 2.0 × 104 g mol−1. The LCST
of the polymer in aqueous solution was determined by UV-Vis
spectroscopy using a JASCO V-630 spectrophotometer
equipped with an EYELA NCB-1200 temperature controller.
The solution was heated from 25 °C to 47 °C whilst the trans-
mittance was recorded at 540 nm. The LCST value was inter-
preted as the temperature at which the solution transmittance
reached 80%.
The crystalline structures of the IONPs were determined by
X-ray diﬀraction (XRD) on a PANalytical X-ray diﬀractometer
using Co Kα radiation (λ = 1.78901 Å). The crystallite size was
extracted from the obtained XRD pattern using the Scherrer
formula. Particle size, size distribution and morphology were
examined with a Hitachi H-7650 transmission electron micro-
scope (TEM) operated at an acceleration voltage of 100 kV.
Samples were prepared by dropping the aqueous IONP suspen-
sion onto a carbon-coated TEM grid and air-dried. The hydro-
dynamic diameter of the IONPs was measured by a dynamic
light scattering instrument (DLS, Zetasizer Nano, Malvern
Instruments).
Colloidal stability of the MNCs in an aqueous dispersion
over time was investigated by monitoring the hydrodynamic
size of the MNCs after preparation and throughout 14 days.
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Eﬀect of pH and diﬀerent dispersion medium on the stability
of the MNCs were also assessed. The magnetic properties of
the NPs were evaluated with a hybrid superconducting
quantum interference device-vibrating sample magnetometer
(SQUID-VSM, Quantum Design). Magnetisation curves were
recorded at 300 K and 5 K, with applied fields up to
5 T. Attenuated total reflectance-Fourier transformed infra-red
(ATR-FTIR) spectra were taken with a Perkin Elmer Spectrum
100 spectrometer. Thermogravimetric analysis (TGA) was used
to monitor the mass loss of a known quantity of MNCs as a
function of temperature. Dry powder was placed on an alu-
minium pan and heated from 25 °C to 500 °C at a rate of 10 °C
min−1 under N2 atmosphere on a Seiko EXSTAR600 TG/DTA
6200 instrument. Prior to the measurement, powder were
heated to 100 °C for 30 min to remove water that could be
present in the sample. In order to determine the grafting
density of the polymer on the NP surface, the mass loss of
bare NPs was also recorded under the same conditions and
used as reference.
Drug conjugation to the MNCs
Conjugation of DOX with the MNCs was achieved through for-
mation of imine bond, also called Schiﬀ base bond, between
the primary amine group of DOX and the aldehyde group of
the P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer. DOX
and MNCs were mixed in PBS (pH = 7.4) with a ratio 1 : 10 w/w
in the presence of TEA. The mixture was shaken gently in the
dark for 24 h at room temperature, thereby leading to the con-
jugation of DOX via imine linkage. The DOX-loaded MNCs
(DOX-MNCs) were retrieved by magnetic separation and
washed thoroughly with PBS until no DOX was detected in the
supernatant (at least 10 washing cycles). The drug conjugation
eﬃciency, η (%), is calculated by measuring the absorbance of
the supernatant at 480 nm of the free DOX remaining in solu-
tion, and after each washing cycle, using the following
equation:
η ¼ Mconjugated
Mfeed
 100 ¼ Mfeed Mexcess
Mfeed
 100 ð1Þ
Here Mfeed is the initial mass of DOX used for the conju-
gation, Mconjugated is the mass of DOX actually conjugated to
the MNCs, and Mexcess is the total mass of DOX found in the
supernatants after the drug loading and each washing step.
The DOX content in DOX-MNCs, WDOX (%), is also evaluated,
and is defined as follow:
WDOX ¼ MconjugatedMcarrier  100 ð2Þ
where Mcarrier is the total mass of the nanosystem DOX-MNCs.
In vitro hyperthermia
Magnetic heating measurements were performed to assess the
heating performances of the nanocomposites using a mag-
netic alternating current hyperthermia (MACH) system (Reso-
nant Circuit Ltd, UK) operating at a frequency f = 960 kHz
and field amplitude H = 6.88 kA m−1. Samples made of 0.5 mL
of MNCs dispersed in water with a concentration of
3 mg mL−1 were placed in the middle of the coil. The increase
in temperature was continuously logged using fibers optic
probes centered in the suspension. Two probes were used in
order to limit possible errors coming from a non-homo-
geneous spatial heating of the suspension. The measurement
was started when the temperature of the suspension was
stabilised to room temperature, and the measurement time
was limited to 10 min. The specific absorption rate (SAR) is
commonly employed to quantify the heat dissipation rate of a
given ferrofluid, even though it is not an intrinsic property of
the system as it is strongly dependent upon the frequency and
field amplitude used during the measurement.
SAR ¼ C
mFe
ΔT
Δt
ð3Þ
where C denotes the specific heat capacity of the sample, mFe
is the iron mass per unit volume of liquid and ΔT/Δt rep-
resents the initial temperature rise rate. On the contrary, the
intrinsic loss parameter (ILP), as defined by Pankhurst et al.,42
can be considered as an intrinsic property of the NPs because
it is obtained by normalizing the SAR by f and H as shown
below:
ILP ¼ SAR
H2f
ð4Þ
Hence one can directly compare the heating eﬃciency
between diﬀerent nanosystems measured under diﬀerent
experimental conditions using ILP. The heating power will
therefore be characterized with the ILP value, but the SAR will
be given as indication.
In vitro drug release behaviour in the absence of AMF
In order to study the pH and temperature dependence of the
drug release kinetics in the absence of an AMF, 6 sets of
experiments were performed. The drug release was studied at
25 °C (room temperature), 37 °C (physiological temperature,
<LCST) and 50 °C (hyperthermia temperature, >LCST). For
each temperature, one sample was held at pH = 7.4 (physio-
logical pH) and another at pH = 5.7 to mimic acidic tumour
pH. Typically, 3.3 mg of DOX-MNCs dispersed in 6 mL of PBS
with the appropriate pH (7.4 or 5.7) were inserted in a Slyde-
A-Lyzer dialysis cassette (MWCO 10 kDa) and dialyzed against
60 mL of PBS with the appropriate pH under mild stirring. A
dialysate volume of 10 times that of the dialysis cassettes was
chosen to insure sink conditions for the DOX. This volume
was required for the dialysis cassette to be fully immersed in
the medium, while the absorbance of DOX in solution is in
the detectable range of UV-Vis. Dialysis set up were either
maintained to room temperature, or placed into preheated
water baths at 37 °C and 50 °C. At predetermined time points
(i.e. 0.25, 0.5, 0.75, 1, 2, 4, 8, 24 and 48 h), 3 mL of dialysate
were taken out for UV-Visible spectroscopy, and replaced with
3 mL of fresh PBS of the appropriate pH to keep the total
volume constant and preserve sink conditions. The DOX
content of the extracted solution was measured by UV-visible
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spectrophotometry and the DOX cumulative release was
determined.
DOX release kinetics analysis
In order to determine the mechanism of drug release and the
release rate, the data obtained from the drug release studies
were fitted with the most relevant kinetic models for our
system, such as first order, Higuchi and Korsmeyer–Peppas
models.43
The first order kinetic release is concentration dependant
and can be expressed as:
Mt ¼ M1½1 expðK1tÞ ð5Þ
where Mt is the amount of drug released at time t, M∞ is the
amount of drug release at infinite time, and K1 is the first
order rate constant. Higuchi model describes drug release
from solid matrices, and is described as
Mt ¼ Kh
ﬃﬃ
t
p ð6Þ
where Kh is the dissolution constant. Korsmeyer–Peppas
model consists in a simple relationship, which describes drug
release from a polymeric matrix, and written as
Mt ¼ M1Kkpt n ð7Þ
where Kkp is the rate constant which is characteristic of the
drug delivery system and n is the exponent. The value of n
changes depending on the release mechanism. In order to
determine the drug release mechanism, first 60% of the drug
release data was fitted with the Korsmeyer–Peppas model. By
comparing the regression coeﬃcient (R2) of the diﬀerent
model, the accuracy of each fitting could be verified. For each
pH and temperature conditions, the model which gives the
highest R2 was considered as the best fit of release data.
Results and discussion
Characterization of the polymer
Polyethylene glycol (PEG) is FDA-approved and is widely used
for biomedical applications, as it is non-toxic to cells and bio-
compatible with both blood and tissue. Therefore, PEG chains
in the P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer
(Fig. 2) provide biocompatibility and water dispersibility to the
nanosystem. Finally, PEG reduces protein adsorption and thus
confers prolonged blood circulation time in the body.44 Co-
polymerizing two PEG chains of diﬀerent length provides
temperature-responsive behaviour to the polymer, with the
possibility to tune the LCST by varying the molar ratio
PEGMA : DEGMA (see ESI, Fig. S1†). A molar ratio of 1 : 2.2 was
selected, as it yields a polymer with a sharp LCST at 40 °C
(higher than the physiological temperature 37 °C and can be
easily reached through magnetic hyperthermia). After this first
step, Mn of the polymer is around 12 000 g mol
−1 (PDI = 1.10)
as determined by SEC. Calculation of the theoretical molecular
weight of the polymer by NMR was in close accordance with
SEC results. Subsequently, a chain extension was carried out
with the TMSPMA and VBA monomers (molar ratio TMSPMA :
VBA = 1 : 4), using P(DEGMA-co-PEGMA) as macro-RAFT agent.
TMSPMA contains a trimethoxysilane group, which will be
used to chemically attach the polymer to the IONP surface via
the formation of covalent Si–O–Fe bond. VBA will be used as
drug storage unit. The successful chain extension was con-
firmed by NMR, dominantly shown by the new signal at
10 ppm corresponding to the proton of the aldehyde group
(see ESI, Fig. S2†). An increase in the molecular weight of the
polymer for 12 000 g mol−1 to 14 000 g mol−1 (PDI = 1.15)
further confirms the polymer was chain extended.
Characterization of IONPs
Fig. 3 shows a TEM image of the as-synthesized IONPs. The
IONPs are spheroidal in shape with an average size of 13.3 ±
2.2 nm calculated from TEM images (n = 305).
Sharp and clearly defined peaks can be observed on the
XRD pattern of the IONPs (Fig. 4), which indicates high degree
of crystallinity of the particles. Diﬀraction peaks matching
with a Fe3O4 magnetite phase (JCPDS PDF no. 00-019-0629)
seem to indicate that the IONPs are primarily magnetite. A
mean crystallite size of 11.1 nm was calculated from the XRD
pattern, which is slightly lower than the particle size obtained
from TEM. The magnetic properties of the IONPs were evalu-
ated at 5 K and 300 K (Fig. 5). Superparamagnetic behaviour
was observed at 300 K with a saturation magnetisation around
70 emu g−1. At 5 K, a hysteresis cycle can be observed due to
the transition to a low temperature blocked state, with a satur-
Fig. 3 TEM image of the as-synthesized IONPs (left) and their size dis-
tribution histogram (right).
Fig. 2 Chemical structure of P(DEGMA-co-PEGMA-b-[TMSPMA-co-
VBA]) polymer.
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ation magnetisation of 82 emu g−1 and a coercive field around
200 Oe.
Characterization of MNCs
The presence of the polymer on the NP surface was confirmed
by FTIR (Fig. 6a). Absorption bands at 1728 cm−1 and
1110 cm−1 correspond to characteristic carbonyl ester bonds
CvO and C–O stretching, respectively. A small aromatic peak
at 1450 cm−1 can also be observed and the small band at
1034 cm−1 is assignable to Si–O bonds.
The average hydrodynamic diameter DH of bare IONPs was
194 nm with a polydispersity index of 0.30 while after
functionalization, the DH of MNCs was reduced to 120 nm
with a polydispersity index of 0.16. Introducing a hydrophilic
polymer coating on the NP surface stabilizes the IONPs, pre-
venting particle agglomeration and therefore also reducing the
attractive inter-particle dipole–dipole interaction and van der
Waals forces. NPs in the size range of 10–200 nm preferentially
accumulate into tumour than healthy tissue owing to the
enhanced permeability and retention (EPR) eﬀect.45 Due to the
defective vascular architecture of tumours and the impaired
lymphatic clearance, NP extravasation and retainment into
tumour tissue is favoured. The DH of the MNCs of 120 nm, is
optimal for the EPR eﬀect.
The organic content of the MNCs was determined using
TGA in the temperature range from 25 °C to 500 °C. Fig. 6b
shows the weight loss of the MNCs as a function of tempera-
ture. Polymer thermal decomposition occurs between 240 °C
and 420 °C with a weight loss of 8.1 wt%, therefore corres-
ponding to the polymer content of the MNCs. An average
number of 24 polymer chains per NP can be calculated.
Colloidal stability of the MNCs
The colloidal stability of the MNCs over time and in diﬀerent
media is of significant importance for biomedical application
purposes. The stability in aqueous suspension of the MNCs
over time was estimated by measuring the change in DH of the
MNCs. No significant changes in hydrodynamic radius was
determined by DLS over two weeks, indicating that the MNCs
remain well dispersed in water (see ESI, Fig. S3a†). As the pH
in the human body can vary considerably, the DH of the MNCs
was measured in aqueous suspension with a pH varying from
2 to 12. The DH of the MNCs remained constant at each
diﬀerent pH condition, suggesting that the pH does not have
any impact on the colloidal stability of the MNCs (see ESI,
Fig. S3b†). Finally, the DH of the MNCs was measured in bio-
logical media, i.e. Dubelcco’s modified Eagles medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
yielding a DH of 147 nm, representing a 27 nm increase as
compared to MNCs in water. However, the MNCs remain
stable in DMEM + 10% FBS for several weeks before any aggre-
gation of the MNCs could be observed. The increase in DH is
Fig. 4 XRD pattern of IONPs. Peaks are indexed according to the refer-
ence pattern for magnetite (JCPDS PDF no. 00-019-0629).
Fig. 5 Magnetization curves of IONPs at 300 K (red line) and 5 K (black
line). The inset shows a zoom into the low magnetic ﬁeld region.
Fig. 6 (a) FTIR spectra and (b) weight loss curves as a function of temp-
erature of as-synthesized IONPs (black line) and MNCs (blue line).
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most likely due to the formation of a protein corona around
the MNCs.46
Magnetic heating measurement
In vitro heating behaviour of an aqueous suspension of MNCs
(3 mg mL−1) subjected to an AMF of frequency f = 960 kHz and
field amplitude H = 6.88 kA m−1 is shown in Fig. 7. The MNCs
exhibited a temperature rise of 16 °C in only 10 min, suﬃcient
to reach hyperthermia temperatures, and yielding an ILP of
1.0 nHm2 K−1 (which translated into a SAR of 47 W g−1). This
ILP value compares favourably to other ILP values obtained for
iron oxide magnetic materials specially synthesized for
hyperthermia applications,26 and commercially available ferro-
fluids with ILP values ranging from 0.15 nHm2 K−1 to
3.1 nHm2 K−1.40,41,47
The concentration of MNCs of 3 mg mL−1 used to deter-
mine their heating abilities, is lower than that used by most
other research groups, and the average concentration of
112 mgFe mL
−1 used by Jordan et al. for clinical trials.18,48–50
Therefore, if higher temperatures needed to be reached in a
shorter time, increasing the concentration of the MNCs in sus-
pension could be feasible.
DOX conjugation eﬃciency
In this work, DOX was chosen as anti-cancer drug because of
its primary amine group, which can react with an aldehyde to
form a Schiﬀ base bond. DOX can then be released by hydro-
lysis of the Schiﬀ base bond without any damage to its chemi-
cal structure. DOX is one of the most widely used
chemotherapeutic drug. It intercalates into DNA and inhibits
the enzyme topoisomerase II, which is necessary for cell divi-
sion and growth, therefore resulting in DNA damage and cell
death. However, its use as anti-cancer agent is still limited by
its detrimental side eﬀects, and especially its cardiotoxicity.51
DOX encapsulation and targeting to the desired site, is there-
fore a very attractive solution to alter the pharmacokinetics
and biodistribution of DOX toward its specific accumulation
in tumour tissue, therefore reducing systematic eﬀects and the
therapeutic dose needed for an eﬃcient therapy. Ideally, the
drug is harmless to healthy tissue while circulating in the body
because it is stored and protected in the MNC until it enters
the tumour, where it is released in high concentrations. Two
methods can be used to encapsulate a drug in an inorganic
core/organic shell NPs: physical loading and chemical conju-
gation via labile bonds. The second method being more
reliable, as chemical binding of the drug limit the leakage in a
great extent through the polymer shell. In this study, DOX was
eﬃciently encapsulated in the MNCs via heat- and acid-cleav-
able amine linkage with a conjugation eﬃciency of η = 82.3%.
The DOX content of the nanocarrier was calculated to be WDOX
= 7.6 wt%. A weight ratio of DOX to MNC of 1 : 10 was used, as
a higher amount of DOX did not lead to significant increase in
the conjugation eﬃciency.
Drug release profile as a function of pH and temperature
Plots for cumulative DOX release as a function of time without
application of an AMF but at diﬀerent temperatures, i.e. 25 °C,
37 °C and 50 °C, in PBS at pH = 7.4 or 5.7 are represented in
Fig. 8. While 50 °C may seem slightly high temperature to
simulate hyperthermia, it was chosen because the existence of
local heating eﬀects in the vicinity of magnetic NPs has been
demonstrated, leading to high temperatures at the magnetic
NP surface without necessarily observing a significant increase
in the surrounding medium.52,53 For example, T. T. T. N’Guyen
and coworkers showed that by subjecting magnetic NPs to an
AMF, they could initiate a retro-Diels–Alder reaction in the
polymer layer functionalizing the magnetic NPs, that generally
requires temperatures up to 90–110 °C.54 Therefore, as the
temperature was maintained via a water bath, we chose to use
50 °C to simulate magnetic hyperthermia conditions instead
of the more widely used temperature of 45 °C. The drug
release profiles of DOX-MNCs under each conditions show two
stages: a rapid release of DOX is obtained within 8 h followed
by a slower rate of release. This behaviour is more pronounced
at pH = 5.7 and 50 °C with 57.8% of DOX released after 8 h
and 85.2% after 48 h, while at pH = 7.4 and 25 °C, 13.6% of
DOX is released after 8 h and 19.7% after 48 h. The pH and
the temperature greatly influence the release behaviour of
DOX. The minimal release of DOX is obtained at pH = 7.4 and
Fig. 7 Typical heating curve of the MNCs dispersed in water with a
concentration of 3 mg mL−1 and subjected to an AMF ( f = 960 kHz and
H = 6.88 kA m−1).
Fig. 8 In vitro cumulative drug release proﬁles of DOX-MNCs dispersed
in PBS at pH = 7.4 or pH = 5.7 at 25 °C, 37 °C and 50 °C.
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25 °C (followed by pH = 7.4 and 37 °C), because at room tem-
perature and physiological pH the imine bond is quite stable
and its hydrolysis kinetic is really slow. The initial small burst
release of DOX at pH = 7.4 and 25 °C is probably due to phys-
ically adsorbed DOX on the outer shell of the polymer layer,
despite the numerous washing of the DOX-MNCs. By using a
pH stimulus, the amount of DOX released at 25 °C is doubled,
with 26.5% of DOX released after 8 h and 39.4% after 48 h.
This is because acidic pH facilitates the release of the drug by
promoting the hydrolysis of the Schiﬀ base bond (pKa of imine
bond is usually around 4). When only the temperature stimu-
lus was used (pH = 7.4 and 50 °C), 38.1% of DOX was released
after 8 h and 72.3% after 48 h. The maximal release of DOX
was found at pH = 5.7 and 50 °C, when the DOX-MNCs were
exposed to both pH and temperature stimuli. The temperature
has two diﬀerent eﬀects: first, it accelerates the rate of the
hydrolysis reaction. Second, the polymer being thermo-respon-
sive, upon reaching the LCST, the polymer becomes hydro-
phobic and shrinks, expelling its aqueous content and
pushing the DOX molecules out at the same time. It should
also be noted that at acidic pH, the primary amine group of
free DOX is protonated (pKa = 8.3), therefore increasing its
solubility in aqueous medium and facilitating its expulsion
out of the polymer layer. Thus, by combining both the eﬀect of
the pH and the temperature, a controlled release of the DOX
can be obtained.
Drug release kinetics and mechanism of release
In this system, the DOX molecules are chemically bound to the
polymer shell of the MNCs. The drug release is therefore
mainly dependant on two mechanisms; firstly, the cleavage of
the imine bond to release the DOX molecules of the bond, and
secondly diﬀusion of DOX molecules from the polymer matrix
to the surrounding dialysis medium.
The use of mathematical models is necessary to predict the
drug release kinetics of a particular system. In this study,
diﬀerent kinetic models i.e. first order kinetic, Higuchi and
Korsmeyer–Peppas were used to fit the release data obtained
for each pH and temperature condition applied. The release
kinetic and mechanism of DOX from the DOX-MNCs nano-
system were therefore determined according to those math-
ematical models. The release parameters for each model (K1,
Kh, Kkp and n) are shown in Table 1 as well as the correlations
values (R2). The first order kinetic model does not fit well with
experimental data as manifested by low R2 values, though an
increasing of R2 can be observed with increasing temperature
and decreasing pH, suggesting a more concentration-depen-
dant release kinetic. Higuchi model also does not fit well with
experimental data, even though it has better R2 values than the
first order model. The highest R2 value is obtained with the
Korsmeyer–Peppas model. Values for the release exponent n
were found to be lower than 0.5 indicating a Fickian diﬀusion
mechanism. However, an increase in the n values with the
increasing temperature and decreasing pH can be observed,
such as at pH 5.7 and 50 °C, the n value reached 0.475, which
becomes close to the limit with anomalous diﬀusion. This can
be attributed to the involvement of the imine bond cleavage,
which becomes more and more important as the pH decreases
and the temperature increases.
Conclusions
In this study, composite magnetic NPs were developed and
their suitability for multimodal cancer therapy, i.e. targeted
controlled drug delivery and localized magnetic hyperthermia
was evaluated. The magnetic core, made of iron oxide, was
synthezised by a microwave-assisted co-precipitation method,
yielding crystalline NPs with a magnetic core size around
13 nm and superparamagnetic behaviour at room temperature.
The iron oxide NPs were functionalized with a thermo-respon-
sive polymer shell [composite NPs (MNCs)], resulting in
increased colloidal stability. The LCST of the polymer could be
easily tuned by varying the initial monomer molar ratio. The
MNCs were found to be performant nanoheaters for magnetic
hyperthermia at relatively low NP concentration. High conju-
gation of the anticancer drug DOX to the MNCs was achieved
through formation of heat- and acid-labile imine bonds. The
dual temperature-and pH-responsive behaviour of the nano-
carrier is an important feature of the nanosystem to control
where and when the drug is released. A burst release of the
drug can be achieved under hyperthermia and tumour acidic
pH conditions, as high temperature and acidic pH were shown
to act as triggers for the release of the drug. At physiological
pH and temperature, the amount of released drug is low; that
is the drug is correctly retained in the nanocarrier, which is
Table 1 Correlation coeﬃcients and release parameters based on drug release data
Temperature (°C) pH (−)
First order Higuchi Korsmeyer–Peppas
K1 R
2 Kh R
2 Kkp n R
2
25 7.4 0.794 0.8188 2.352 0.8523 8.181 0.277 0.9918
25 5.7 0.288 0.8861 5.510 0.9204 12.530 0.361 0.9893
37 7.4 0.293 0.8821 4.589 0.9179 10.548 0.363 0.9911
37 5.7 0.353 0.9039 6.232 0.9040 14.841 0.378 0.9981
50 7.4 0.127 0.9385 10.585 0.9844 14.520 0.451 0.9913
50 5.7 0.259 0.9536 12.282 0.9177 22.175 0.475 0.9875
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desirable in clinical applications to limit distribution of the
drug to healthy tissues and unwanted side eﬀects. The nano-
system developed here is therefore promising for thermo-
chemotherapy applications. It is necessary to investigate the
behaviour of the drug release under application of an AMF at
physiological pH and acidic tumour pH. Indeed, as the heat
comes from the core of the nanocarrier, the release profiles
may be diﬀerent as when the heating is applied through a
water bath. Moreover, as already mentioned earlier in the text,
in magnetic hyperthermia, studies have shown the existence of
local heating eﬀects in the vicinity of magnetic NPs leading to
high temperatures at the magnetic NP surface without necess-
arily observing a significant increase in the surrounding
medium.52,53 This phenomenon could favourably influence
the drug release behaviour as the heat is directly transmitted
to the polymer shell. In future work, the drug release under
application of an AMF will be studied, and the potential of the
DOX-MNCs for thermo-chemotherapy will be tested on cells
and in vivo.
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